BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31515282)

  • 1. The Deubiquitinating Enzyme Inhibitor PR-619 is a Potent DNA Topoisomerase II Poison.
    Cowell IG; Ling EM; Swan RL; Brooks MLW; Austin CA
    Mol Pharmacol; 2019 Nov; 96(5):562-572. PubMed ID: 31515282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleolar translocation of human DNA topoisomerase II by ATP depletion and its disruption by the RNA polymerase I inhibitor BMH-21.
    Morotomi-Yano K; Yano KI
    Sci Rep; 2021 Nov; 11(1):21533. PubMed ID: 34728715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
    Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
    Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
    Swan RL; Poh LLK; Cowell IG; Austin CA
    Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Role for VCP/p97 in the Processing of Drug-Stabilized TOP2-DNA Covalent Complexes.
    Swan RL; Cowell IG; Austin CA
    Mol Pharmacol; 2021 Jul; 100(1):57-62. PubMed ID: 33941661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clarifying the Mechanism of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα and IIβ.
    Keck JM; Conner JD; Wilson JT; Jiang X; Lisic EC; Deweese JE
    Chem Res Toxicol; 2019 Oct; 32(10):2135-2143. PubMed ID: 31512855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of TDP2 on the Level of TOP2-DNA Complexes and SUMOylated TOP2-DNA Complexes.
    Lee KC; Swan RL; Sondka Z; Padget K; Cowell IG; Austin CA
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
    Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
    Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
    Atwal M; Lishman EL; Austin CA; Cowell IG
    Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
    Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
    Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloperoxidase inhibition protects bone marrow mononuclear cells from DNA damage induced by the TOP2 poison anti-cancer drug etoposide.
    Cowell IG; Austin CA
    FEBS Open Bio; 2024 Jun; 14(6):1001-1010. PubMed ID: 38531625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-associated H58Y mutation affects the nuclear dynamics of human DNA topoisomerase IIβ.
    Morotomi-Yano K; Hiromoto Y; Higaki T; Yano KI
    Sci Rep; 2022 Nov; 12(1):20627. PubMed ID: 36450898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms to Repair Stalled Topoisomerase II-DNA Covalent Complexes.
    Swan RL; Cowell IG; Austin CA
    Mol Pharmacol; 2022 Jan; 101(1):24-32. PubMed ID: 34689119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncofetal HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology.
    Ahmed SM; Dröge P
    Mol Oncol; 2019 Oct; 13(10):2062-2078. PubMed ID: 31271486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
    Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
    Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.
    Karapetian M; Tsikarishvili S; Kulikova N; Kurdadze A; Zaalishvili G
    DNA Repair (Amst); 2020 Mar; 87():102772. PubMed ID: 31877465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.
    Shapiro AB; Austin CA
    Anal Biochem; 2014 Mar; 448():23-9. PubMed ID: 24309019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
    Ma Y; North BJ; Shu J
    Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poly(ADP-ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis.
    Meyer-Ficca ML; Lonchar JD; Ihara M; Meistrich ML; Austin CA; Meyer RG
    Biol Reprod; 2011 May; 84(5):900-9. PubMed ID: 21228215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.
    Menendez D; Anand JR; Murphy CC; Bell WJ; Fu J; Slepushkina N; Buehler E; Martin SE; Lal-Nag M; Nitiss JL; Resnick MA
    Oncotarget; 2022; 13():332-346. PubMed ID: 35178190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.